Scabies, comparison of Lindane1% vs. Permethrin 5%
Phase 2
- Conditions
- Scabies.Sarcoptic itch
- Registration Number
- IRCT2013081212125N1
- Lead Sponsor
- Vice Chancellor for Reserach, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1-Scabies disease; 2-Consent for research; 3-Being at the age between 2-80 years.
Exclusion criteria: 1-Pregnant and lactating women; 2-Patients with history of seizure; 3-Patients with systemic diseases.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of Scabies skin lesions. Timepoint: 2 and 4 weeks after the drug therapy. Method of measurement: With photography of lesions and their counting.
- Secondary Outcome Measures
Name Time Method octurnal itching. Timepoint: 2 and 4 weeks after drug therapy. Method of measurement: Asking the patients.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Lindane1% and Permethrin5% in targeting Sarcoptes scabiei nervous system pathways?
How does the efficacy of Lindane1% compare to Permethrin5% as standard-of-care for scabies in IRCT2013081212125N1?
Which biomarkers correlate with treatment response in scabies patients using Lindane1% or Permethrin5% in phase II trials?
What adverse events are associated with Lindane1% versus Permethrin5% in scabies treatment, and how are they managed?
Are there alternative scabicides or combination therapies with Lindane1% or Permethrin5% for resistant scabies cases?